213 related articles for article (PubMed ID: 9336139)
1. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure.
Wirth A; Corry J; Laidlaw C; Matthews J; Liew KH
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):599-607. PubMed ID: 9336139
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).
Radman I; Basić N; Labar B; Kovacević J; Aurer I; Bogdanić V; Zupancić-Salek S; Nemet D; Jakić-Razumović J; Mrsić M; Santek F; Grgić-Markulin L; Boban D
Ann Oncol; 2002 Oct; 13(10):1650-5. PubMed ID: 12377656
[TBL] [Abstract][Full Text] [Related]
5. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
8. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.
Ng AK; Li S; Neuberg D; Silver B; Stevenson MA; Fisher DC; Mauch PM
Ann Oncol; 2004 Feb; 15(2):270-5. PubMed ID: 14760121
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
Noordijk EM; Carde P; Mandard AM; Mellink WA; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Dupouy N
Ann Oncol; 1994; 5 Suppl 2():107-12. PubMed ID: 7515643
[TBL] [Abstract][Full Text] [Related]
10. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
11. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
13. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
[TBL] [Abstract][Full Text] [Related]
15. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tirelli U; Bortolus R; van 't Veer MB; Lybeert ML; Keuning JJ; Carde P; Girinsky T; van der Maazen RW; Tomsic R; Vovk M; van Hoof A; Demeestere G; Lugtenburg PJ; Thomas J; Schroyens W; De Boeck K; Baars JW; Kluin-Nelemans JC; Carrie C; Aoudjhane M; Bron D; Eghbali H; Smit WG; Meerwaldt JH; Hagenbeek A; Pinna A; Henry-Amar M;
N Engl J Med; 2003 Jun; 348(24):2396-406. PubMed ID: 12802025
[TBL] [Abstract][Full Text] [Related]
16. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
17. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
18. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience.
Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R
Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307
[TBL] [Abstract][Full Text] [Related]
19. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
20. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
Rüffer JU; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A;
Leuk Lymphoma; 2005 Nov; 46(11):1561-7. PubMed ID: 16236610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]